Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
- Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen
August 1, 2014
- JPA’s Abe Makes Chuikyo Debut, Says No to Annual Drug Price Revisions
July 31, 2014
- Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
- MHLW Bulletin Notifies of Revised Package Inserts Warning Concurrent Use of ARBs, ACE Inhibitors
July 30, 2014
- NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
- MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
- Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25
July 29, 2014
- Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official
July 29, 2014
- PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8
July 29, 2014
- Editor’s Pick: Five Healthcare News Headlines for July14 - July 25
July 28, 2014
- Health Minister Calls for Strict Compliance with Transparency Guidelines
July 28, 2014
- Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs
July 28, 2014
- PDMA to Issue Practical Notification on Submission of Electronic Applications for Approval Next January at Earliest
July 28, 2014
- MHLW Suggests Regulation for Research Likely to Be Used in Ads
July 25, 2014
- Cabinet Approves Health, Medical Strategy
July 24, 2014
- Toshihiko Takeda Appointed Councilor in Charge of Health Insurance
July 24, 2014
- PMDA Reviewing Infliximab for Risk of Rhabdomyolysis
July 24, 2014
- PAFSC’s First Committee to Discuss MSD’s Insomnia Drug on Aug. 1
July 24, 2014
- Ex-Novartis Employee Indicted on Additional Charges, Prosecutors to Wind Up Probe: Reports
July 23, 2014
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…